Metastatic Castration-Resistant Prostate Cancer (mCRPC) Clinical Trial
Official title:
An Open-label Dosimetry, Biodistribution, Tolerability and Safety Study of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Moderately and Severely Impaired and With Normal Renal Function.
This study will address health authorities' requests to determine whether moderate and severe renal impairment have an impact on the biodistribution, dosimetry and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) administered to participants with progressive PSMA-positive metastatic castration-resistant prostate cancer. The study will also characterize the risk of QT prolongation of AAA617 in this participant population.
This open-label, non-randomized, multicenter, single arm phase II study in mCRPC participants aims to better characterize the safety and tolerability of AAA617 in participants with moderate and severe renal impairment compared with normal renal function. Since both severe and moderate renal impairment have very low incidence within mCRPC participant population compared to participants with normal renal function, the enrollment will occur in parallel for the 3 cohorts; participants will be stratified in one of the three cohorts (A:normal, B: moderate or C: severe) based on their eGFR at screening. All participants will undergo a 68Ga-PSMA-11 PET/CT scan at screening to confirm PSMA positivity. Participants will receive a dose of 7.4 GBq (±10%) of AAA617 once every 6 weeks for a planned 6 cycles for cohorts A and B and for 3 cycles (and 3 additional cycles) for cohort C. After treatment period, participants will be asked to join a long term follow up (LTFU) study to monitor their safety up to 10 years after the 1st dose of AAA617. In case of the LTFU study is not available at the time of end of treatment period (safety follow-up visit), participants will continue in Long Term Follow-up period in this study for up to one year until they can roll over into the separate LTFU study. The primary outcome will be to determine the effect of radiation absorption in kidney and other organs at risk as well as the concentration in blood and radioactivity in urine in PSMA- positive mCRPC participants with moderate and severe renal impairment. In addition, the study will assess the relationship between drug concentrations and QTcF. 20 participants with 6 countries are expected to be included with at least 6 evaluable participantts per cohort. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01977651 -
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
|
Phase 4 | |
Recruiting |
NCT04015622 -
PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA
|
Phase 2 | |
Recruiting |
NCT06344715 -
Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.
|
Phase 1 | |
Recruiting |
NCT05983198 -
A Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With PSMA-positive Prostate Cancer With or Without Prior 177Lu-PSMA Radioligand Therapy.
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06134232 -
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
|
Phase 3 | |
Recruiting |
NCT06126731 -
Combination Study of Antibiotics With Enzalutamide (PROMIZE)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05806814 -
Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05658003 -
A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
|
Phase 2 | |
Active, not recruiting |
NCT05670106 -
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC
|
Phase 2 | |
Recruiting |
NCT04691804 -
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
|
Phase 3 | |
Completed |
NCT03896984 -
Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).
|
||
Recruiting |
NCT06334432 -
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03074032 -
Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer
|
Phase 1 | |
Recruiting |
NCT05032040 -
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
|
Phase 2 | |
Completed |
NCT03071328 -
INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers
|
Early Phase 1 | |
Active, not recruiting |
NCT02649790 -
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
|
Phase 1/Phase 2 | |
Completed |
NCT03030885 -
Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
|
Phase 1 | |
Terminated |
NCT03712930 -
Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency
|
Phase 2 | |
Recruiting |
NCT06241846 -
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
|
Phase 2 |